Abstract
A series of non-covalent piperidine-containing peptidyl derivatives with various substituents at side chains of different residues were designed, synthesized and evaluated as proteasome inhibitors. After proteasome inhibitory evaluations of all the synthesized target compounds, selected ones were tested for their anti-proliferation activities against three multiple myeloma (MM) cell lines. 8 analogues displayed more potent activities than carfilzomib, and the most promising compound 24 showed IC50 values of 0.8 ± 0.2 nM against 20S proteasome and 8.42 ± 0.74 nM, 7.14 ± 0.52 nM, 14.20 ± 1.08 nM for RPMI 8226, NCI-H929 and MM.1S cell lines, respectively. Additionally, mechanisms of anti-cancer activity of representative compound 24 were further investigated. Apoptosis of RPMI-8226 cells were achieved through accumulating polyubiquitin and inducing the cleavage of caspase and PARP. Besides, half-life in rat plasma of compound 24 was prolonged after optimization, which would be helpful for increasing in vivo activities of this series of derivatives. All the studies confirmed that piperidine-containing non-covalent proteasome inhibitors can be potential leads for anti-MM drug development.
References
Oct 7, 1994·Cell·A Ciechanover
Mar 28, 2002·Physiological Reviews·Michael H Glickman, Aaron Ciechanover
Dec 2, 2004·Biochimica Et Biophysica Acta·Cecile M Pickart, Michael J Eddins
Jul 17, 2010·The Biochemical Journal·Christopher BlackburnJonathan L Blank
Sep 30, 2010·Bioorganic & Medicinal Chemistry Letters·Christopher BlackburnKenneth M Gigstad
Mar 28, 2013·Current Medicinal Chemistry·Jiankang ZhangYongzhou Hu
Jan 3, 2014·The Journal of Clinical Investigation·Nathaniel M Weathington, Rama K Mallampalli
Jan 21, 2015·Structure·Wayne HarshbargerJames Sacchettini
Aug 22, 2015·Oncotarget·Tatyana A GrigorevaNickolai A Barlev
Feb 6, 2016·Drugs·Matt Shirley
Jun 19, 2016·Bioorganic & Medicinal Chemistry·Arwin J BrouwerRob M J Liskamp
Dec 28, 2016·European Journal of Medicinal Chemistry·Rangxiao ZhuangJiankang Zhang
Jan 7, 2017·Oncotarget·Bruno O VilloutreixMichèle Reboud-Ravaux
Jun 24, 2017·Bioorganic & Medicinal Chemistry·Beatriz BlancoAndrew D Abell
Aug 31, 2017·ACS Central Science·Philipp M Cromm, Craig M Crews
Oct 20, 2017·Cancer Metastasis Reviews·Claire L SoaveQ Ping Dou
Jun 24, 2018·Bioorganic & Medicinal Chemistry·Meng LeiYongqiang Zhu
Aug 31, 2018·European Journal of Medicinal Chemistry·Doleshwar NiroulaRodolfo Tello-Aburto
Oct 23, 2019·Bioorganic & Medicinal Chemistry·Lingkuan MengFei Yu